These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28157691)

  • 21. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial.
    Wen X; Wang L; Li F; Yu X
    J Ovarian Res; 2024 Jul; 17(1):147. PubMed ID: 39014475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
    Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.
    Wei W; Zhao H; Wang A; Sui M; Liang K; Deng H; Ma Y; Zhang Y; Zhang H; Guan Y
    Eur J Endocrinol; 2012 Jan; 166(1):99-105. PubMed ID: 22019891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
    Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
    Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome.
    Oktenli C; Ozgurtas T; Dede M; Sanisoglu YS; Yenen MC; Yesilova Z; Kenar L; Kurt YG; Baser I; Smith J; Cianflone K
    Gynecol Endocrinol; 2007 Dec; 23(12):710-5. PubMed ID: 18075846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
    Feng W; Jia YY; Zhang DY; Shi HR
    Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
    Soldat-Stanković V; Popović-Pejičić S; Stanković S; Prtina A; Malešević G; Bjekić-Macut J; Livadas S; Ognjanović S; Mastorakos G; Micić D; Macut D
    J Endocrinol Invest; 2022 Mar; 45(3):583-595. PubMed ID: 34665453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
    Underdal MO; Stridsklev S; Oppen IH; Høgetveit K; Andersen MS; Vanky E
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2408-2413. PubMed ID: 29659896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
    Sun X; Wu X; Zhou Y; Yu X; Zhang W
    Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
    Wu H; Ruan X; Jin J; Mueck AO
    Gynecol Endocrinol; 2015 Jul; 31(7):548-51. PubMed ID: 26004979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.
    Rajagopal G; Reddy AP; Venkata Harinarayan C; Suresh V; Bitla A; P V L N Rao S; Sachan A
    Metab Syndr Relat Disord; 2012 Aug; 10(4):273-9. PubMed ID: 22468948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.